pyridine - chloroacetic acid | 933-24-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: pyridine - chloroacetic acid
• 英文别名: 2-Chloroacetic acid;pyridine；2-chloroacetic acid;pyridine
• CAS: 933-24-4
• 化学式: C₂H₃ClO₂*C₅H₅N
• 分子量: 173.599
• InChiKey: SVJXEFIHRCKUJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.39
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吡啶 、 氯乙酸 以 氯仿 为溶剂， 生成 pyridine - chloroacetic acid
  参考文献：
  名称：

  氢卤化吡啶鎓盐的氢键物种。2.在非质子传递溶剂中的测温行为

  摘要：

  DOI：

  10.1021/j150656a044

文献信息

• INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shimizu Kazuo

  公开号：US20120015972A1

  公开（公告）日：2012-01-19

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. That is, the present invention relates to indolizine derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In the formula, ring U represents aryl or heteroaryl; R 1 represents halogen, a hydroxy group or the like; R 2 represents halogen, a hydroxy group, alkyl, alkoxy, alkyl substituted by fluorine, alkoxy substituted by fluorine or the like; m represents a number from 0 to 2; n represents a number from 0 to 3; and R 3 represents hydrogen, fluorine or the like.

  本发明提供了作为与异常血清尿酸水平相关的疾病的预防或治疗剂的化合物。也就是说，本发明涉及由以下式（I）所表示的吲哚啉衍生物，具有黄嘌呤氧化酶抑制活性，并且作为与血清尿酸水平异常相关的疾病的预防或治疗剂，其前药，其盐或类似物。在该式中，环U代表芳基或杂环芳基；R1代表卤素，羟基或类似物；R2代表卤素，羟基，烷基，烷氧基，氟取代的烷基，氟取代的烷氧基或类似物；m代表0到2之间的数字；n代表0到3之间的数字；R3代表氢，氟或类似物。
• [EN] PROCESS FOR THE PREPARATION OF PHOSPHORIC ACID MONO- (L-{4- [(S) -5- (ACETYLAMINOMETHYL) - 2 - OXO - OXAZOLIDIN- 3 - YL] - 2, 6 - DIFLUOROPHENYL} - 4 -METHOXYMETHYLPIPERIDIN- 4 - YL) ESTER<br/>[FR] PROCÉDÉ DE SYNTHÈSE D'ESTER DE MONO-(1-{4-[(S)-5-(ACÉTYLAMINO-MÉTHYL)-2-OXO-OXAZOLIDIN-3-YL]-2,6-DIFLUORO PHÉNYL}-4-MÉTHOXYMÉTHYL-PIPÉRIDIN-4-YLE) D'ACIDE PHOSPHORIQUE
  申请人：WOCKHARDT LTD

  公开号：WO2012059823A1

  公开（公告）日：2012-05-10

  The invention relates to a process to prepare pharmacologically active phosphoric acid mono-(1-4-[(S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,6-difluoro phenyl}-4-methoxy methyl-piperidin-4-yl) ester.

  这项发明涉及一种制备药理活性磷酸单-(1-4-[(S)-5-(乙酰氨基甲基)-2-氧代-噁唑啉-3-基]-2,6-二氟苯基}-4-甲氧基甲基-哌啶-4-基)酯的方法。
• Activators for oligonucleotide synthesis
  申请人：——

  公开号：US20030191304A1

  公开（公告）日：2003-10-09

  The present invention relates to improved methods for the preparation of nucleoside phosphoramidites and oligonucleotides. In one aspect, the methods of the invention are used to prepare phosphitylating reagents using pyridinium salts as activators. In a further aspect, the methods of the invention are used to prepare internucleoside linkages using activators which include at least one pyridinium salt and at least one substituted imidazole. In a further aspect, methods are provided preparation of internucleoside linkages between nucleosides having 2′-substituents using imidazolium or benzimidazolium salts as an activator. In a further aspect, methods are provided preparation of internucleoside linkages between nucleosides having bioreversible protecting group that confers enhanced chemical and biophysical properties, without exocyclic amine protection, using imidazolium or benzimidazolium salts as an activator.

  本发明涉及改进的核苷酸磷酰胺和寡核苷酸制备方法。在一个方面，本发明的方法用于使用吡啶盐作为活化剂制备磷酸化试剂。在进一步的方面，本发明的方法用于使用至少一种吡啶盐和至少一种取代咪唑作为活化剂制备核苷酸间连接。在另一个方面，提供了一种方法，用于使用咪唑盐或苯并咪唑盐作为活化剂，制备具有2'-取代基的核苷酸之间的核苷酸间连接。在另一个方面，提供了一种方法，用于使用咪唑盐或苯并咪唑盐作为活化剂，在不进行外环胺保护的情况下，制备具有生物可逆保护基的核苷酸之间的核苷酸间连接，从而使其具有增强的化学和生物物理性质。
• PROCESS FOR THE PREPARATION OF PHOSPHORIC ACID MONO-(1--4-METHOXYMETHYL-PIPERIDIN-4-YL) ESTER
  申请人：Patil Vijaykumar Jagdishwar

  公开号：US20130296569A1

  公开（公告）日：2013-11-07

  The invention relates to a process to prepare pharmacologically active phosphoric acid mono-(1-4-[(S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,6-difluoro phenyl}-4-methoxy methyl-piperidin-4-yl)ester.

  本发明涉及一种制备具有药理活性的磷酸单酯化合物的过程，该磷酸单酯化合物的化学结构为：mono-(1-4-[(S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,6-difluoro phenyl}-4-methoxy methyl-piperidin-4-yl)ester。
• METHODS OF REFOLDING PROTEINS
  申请人：——

  公开号：US20020052026A1

  公开（公告）日：2002-05-02

  Methods are disclosed for refolding proteins of the TGF-&bgr; family of proteins. The methods employ as refolding agents one or more compounds which are non-detergent zwitterionic compounds, such as sulfobetaines, substituted pyridines, substituted pyrroles and acid substituted aminocyclohexanes.

  本发明公开了使 TGF-&bgr 蛋白家族的蛋白质重新折叠的方法。这些方法采用一种或多种非去垢齐聚物化合物作为重折叠剂，例如磺基甜菜碱、取代的吡啶、取代的吡咯和酸取代的氨基环己烷。